Targets in ALS: designing multidrug therapies
- 1 May 2006
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 27 (5), 267-273
- https://doi.org/10.1016/j.tips.2006.03.009
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNANeurobiology of Disease, 2005
- Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosisExperimental Neurology, 2005
- EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relativesEuropean Journal of Neurology, 2005
- COPPER-ZINC SUPEROXIDE DISMUTASE AND AMYOTROPHIC LATERAL SCLEROSISAnnual Review of Biochemistry, 2005
- Merits of a New Drug Trial for ALS?Science, 2005
- Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosisAnnals of Neurology, 2005
- GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALSHuman Gene Therapy, 2005
- Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosisNeuroReport, 2005
- Stem Cell Therapy for ALS: Hope and Reality A discussion paper from the Executive of the European ALS ConsortiumAmyotrophic Lateral Sclerosis, 2003
- Clinical Trials in ALS: An OverviewSeminars in Neurology, 2001